<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04368247</url>
  </required_header>
  <id_info>
    <org_study_id>SFI 003</org_study_id>
    <nct_id>NCT04368247</nct_id>
  </id_info>
  <brief_title>Skin Fluorescent Imaging (SFI) System in Patients With Nevi</brief_title>
  <official_title>Skin Fluorescent Imaging (SFI) System in Patients With Nevi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orlucent, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orlucent, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Sponsor has developed the Skin Fluorescent Imaging (SFI) system, an in vivo imaging&#xD;
      modality, for the purpose of providing physicians with insight into the biological changes&#xD;
      occurring during tissue remodeling in a nevus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SFI system, a non-invasive point-of-care imaging system, is able to detect markers&#xD;
      associated with tissue remodeling and thus provide real-time information about biological and&#xD;
      structural changes occurring in nevi indicative of dysplastic transition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Establish the performance of SFI</measure>
    <time_frame>1year</time_frame>
    <description>Establish the performance (sensitivity and specificity) for SFI in comparison to dysplasia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare SFI to clinical diagnosis.</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of the SFI score ( 0 to 10) to the clinical diagnosis of the physician assessing and the pathologist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To establish the tolerability of SFI Testing by documenting minimal, transient events that occur with reagent application.</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events will be collected to ensure overall safety of reagents and imaging</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Nevus</condition>
  <condition>Dysplasia; Epithelial</condition>
  <arm_group>
    <arm_group_label>Nevi undergoing biopsy per SOC</arm_group_label>
    <description>Subjects with Nevi who will as part of their standard of care, will undergo biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Skin Fluorescent Imaging</intervention_name>
    <description>Application of reagents, then imaging and scoring</description>
    <arm_group_label>Nevi undergoing biopsy per SOC</arm_group_label>
    <other_name>SFI 003 Imaging</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      If the Site specific pathology lab will not allow the sponsor to make a digital image of the&#xD;
      original slide, then the Sponsor is asking that a duplicate slide be provided for digital&#xD;
      scanning. Once scanning is complete these additional slides may not be returned to the site.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who present with suspicious nevus/nevi and who require a Standard of Care (SOC)&#xD;
        biopsy of the atypical nevi will be able to participate in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to be eligible to participate in this study a subject must meet all of the&#xD;
        following criteria:&#xD;
&#xD;
          -  Provide a signed and dated informed consent form&#xD;
&#xD;
          -  Age â‰¥ 18 years old&#xD;
&#xD;
          -  Subjects must present with suspicious atypical nevi scheduled for a biopsy*&#xD;
&#xD;
          -  Nevi with at least 1 cm of skin surrounding the mole&#xD;
&#xD;
          -  Nevi must be accessible to the SFI imaging device&#xD;
&#xD;
          -  Excisional or a tangential excision with a dept of 1 to 2 mm biopsy will be performed&#xD;
             for the mole tested within 21 days of testing.&#xD;
&#xD;
          -  Nevi with clinically atypical features&#xD;
&#xD;
        Only 1 mole per eligible subject will be SFI tested in this study. *NOTE: a subset of&#xD;
        patients (~10%) with benign nevi (by clinical observation) who wish to have nevi removed&#xD;
        for cosmetic reasons will be enrolled as negative controls.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        An individual who meets any of the following criteria will be excluded from participation&#xD;
        in this study:&#xD;
&#xD;
          -  Subjects who are younger than 18 years old&#xD;
&#xD;
          -  Lesions that are consistent with&#xD;
&#xD;
             - Features of Keratosis and keratin plugs&#xD;
&#xD;
               -  Basal Cell Carcinoma&#xD;
&#xD;
               -  Squamous Cell Carcinoma&#xD;
&#xD;
               -  Challenging anatomical location (e.g., body cervices)&#xD;
&#xD;
          -  Subjects with nevi that fit the inclusion criteria but are:&#xD;
&#xD;
               -  Less than 1 cm from the eyes&#xD;
&#xD;
               -  On the palms of the hands or soles of the feet&#xD;
&#xD;
               -  Associated with scar tissue&#xD;
&#xD;
               -  Mucosal lesions&#xD;
&#xD;
               -  Ulcerated lesions / breached skin&#xD;
&#xD;
               -  Lesions with some clinical certainty of being melanomas (large, dark, etc.)&#xD;
&#xD;
               -  Any nevi with ink marking including tattoos, on or adjacent to the nevi&#xD;
&#xD;
               -  Lesions treated with local anesthesia such as lidocaine prior to enrollment&#xD;
&#xD;
               -  Lesions larger than 20 mm or too large to allow imaging&#xD;
&#xD;
               -  Subject is known to be pregnant&#xD;
&#xD;
               -  Subject who is mentally or physically unable to comply with all aspects of the&#xD;
                  study&#xD;
&#xD;
               -  Subject who is undergoing systemic cancer treatment within 6 months of SFI&#xD;
                  testing&#xD;
&#xD;
               -  Subject with hypersensitivity to any of the SFI reagents&#xD;
&#xD;
               -  Subjects with known sensitivity to fluorescent dyes&#xD;
&#xD;
               -  Any subject who has previously participated (testing to biopsy) in SFI 003&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Cathy Shachaf, PhD</last_name>
    <role>Study Director</role>
    <affiliation>President</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BRANDI DUNN</last_name>
    <phone>2107714024</phone>
    <email>brandi.dunn@orlucent.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cathy Shachaf</last_name>
    <email>cshachaf@orlucent.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Dermatology Clinical Research, Inc</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anchal Dhawan</last_name>
    </contact>
    <investigator>
      <last_name>Sunil Dhawan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Quest Dermatology Research</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lawrence Osman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lawrence Osman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Solano Dermatology Associates</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94590</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serena Mraz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Serena Mraz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Doug Grossman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Douglas Grossman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nevus</keyword>
  <keyword>Atypical Nevi</keyword>
  <keyword>Mole</keyword>
  <keyword>Skin Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

